Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Its especially beneficial for dry, normal, or mature skin types ready to commit to a consistent anti-aging routine.
We just dont know
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial
Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Miller PLoS ONE.2013
US$ 24.75
US$ 29.03
US$ 22.03
US$ 20.75
